Is Enveric Biosciences, Inc. (ENVB) a Buy, Sell, or Hold?
NASDAQ : ENVB
Enveric Biosciences, Inc.
$1.5212 USD
-$0.02 (-1.22%)
- Volume
- 18.86K
- Average Volume
- 203.54K
- Market Capitalization
- $908.18K
- P/E Ratio
- -0.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $17.64
- Year Low
- $1.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.67
Company Overview
NASDAQ
Joseph Edward Tucker
Biotechnology
Healthcare
ENVB
6
US
USD
Liquidity Metrics
0.00
11.67
11.66
10.66
0.00
Sales & Valuation
-$
0.00
0.45
-0.11
-5.30
Profitability
-$36.24
-$12.13M
0.00%
0.00%
-220.99%
-148.88%
P/E Metrics
-0.06
0.00
0.00
Analyst Price Target & Rating
2/5
4 Analysts
%
Financial Health Scores
-32.18
2/9
$4.91M
$5.52M
$460.68K
-$8.22M
Key Metrics (TTM)
-$3.99M
0.00
0.49
11.67
-220.99%
-162.43%
-353.41%
-870.87%
-641 days
Company Executives
| Name | Title |
|---|---|
| Joseph Edward Tucker | Chief Executive Officer & Director |
| Peter J. Facchini | Chief Innovation Officer |
| Kevin Coveney | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Enveric Biosciences, Inc. (NASDAQ:ENVB) Stock
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida. ...
2026-08-05 09:30:17
Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinforcing the non-hallucinogenic nature of its primary drug candidate, EB-003.
2026-08-05 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003. Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay,.
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
2026-07-28 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. “The final guidance reflects the FDA's continued engagement with clinical developme.
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
2026-06-29 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within t.
Enveric Biosciences Announces Participation in 2026 BIO International Convention
2026-06-16 10:01:00
Enveric Biosciences (NASDAQ: ENVB) (âEnvericâ or the âCompanyâ), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics t
Enveric Biosciences Announces Participation in 2026 BIO International Convention
2026-06-16 09:28:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxic.
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
2026-06-09 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the UBS 3rd Virtual CNS Day being held on June 15, 2026. During the virtual event, members of Enveric's management team will conduct one-on-one meetings with registered investors to discuss the company's busine.
2026-06-02 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the Initiation of Investigational New Drug (IND)-enabling Genotoxicity studies of its lead candidate neuroplastogen, EB-003. The initiated Good Laboratory Practice (GLP) studies will evaluate the potential for the compound to interact with DNA and.
Frequently Asked Questions
-
What is the current Enveric Biosciences, Inc. (ENVB) stock price?
-
Enveric Biosciences, Inc.(NASDAQ:ENVB) stock price is $1.5212 in the last trading session. During the trading session, ENVB stock reached the peak price of $17.64 while $1.25 was the lowest point it dropped to. The percentage change in ENVB stock occurred in the recent session was --1.22% while the dollar amount for the price change in ENVB stock was -$0.02.
-
ENVB's industry and sector of operation?
-
The NASDAQ listed ENVB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ENVB?
-
Joseph Edward Tucker | Chief Executive Officer & Director
Peter J. Facchini | Chief Innovation Officer
Kevin Coveney | Chief Financial Officer
|
| -
How many employees does ENVB have?
-
Number of ENVB employees currently stands at 6. ENVB operates from 245 First Street, Cambridge, MA 02142, US.
-
Link for ENVB official website?
-
Official Website of ENVB is: https://www.enveric.com
-
How do I contact ENVB?
-
ENVB could be contacted at phone #239 302 1707 and can also be accessed through its website. ENVB operates from 245 First Street, Cambridge, MA 02142, US.
-
How many shares of ENVB are traded daily?
-
The average number of ENVB shares traded daily for last 3 months was 203.54K.
-
What is the market cap of ENVB currently?
-
The market value of ENVB currently stands at $908.18K with its latest stock price at $1.5212